Molecular Pathology Laboratory Network, Inc. (MPLN) is committed to complying with the Health Insurance Portability and Accountability Act (HIPAA) and to protecting the confidentiality of every individual's laboratory test results and other Protected Health Information (PHI). To ensure protection of PHI, we have implemented strict policies and procedures to comply with the Proposed Security Standards and other applicable federal and state laws and regulations. In addition, we continuously monitor and audit these processes for effectiveness and compliance. Our Patient Privacy Notice, which applies to Geneuity Clinical Research Services, may be found here:
At MPLN, we are dedicated to providing the highest quality of service to our clients in compliance with federal, state, and local laws and regulations. In turn, we employ highly qualified, licensed medical technologists, and actively pursue a rigorous program of continuous quality assessment and improvement in all areas of laboratory operations. Our commitment to quality applies to our technical operations as well as our business operations, including marketing practices and billing. Through constant monitoring and evaluation of our services with internal and external client satisfaction assessments, we ensure that we are meeting and exceeding client expectations. MPLN is certified by the Clinical Laboratory Improvement Amendments (CLIA), accredited by the College of American Pathologists (CAP), and licensed by the states of Tennessee, New York, Florida, California, and Maryland.
Click here for Laboratory Licenses
Analyte Specific Reagent. Molecular Pathology Laboratory Network, Inc. is certified by CLIA for high complexity clinical testing. Federally required statement.This test was developed and its performance characteristics determined by Molecular Pathology Laboratory Network, Inc. It has not been cleared or approved by the US Food and Drug Administration. However, the FDA has determined that approval and clearance are not necessary.
Testing for FLT3 is performed at Laboratory for Personalized Molecular Medicine (LabPMM.com) of San Diego, California pursuant to patents licensed from Takara Bio of Otsu, Japan.